First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Federica Pecci(University of Parma), Xiuning Le(The University of Texas MD Anderson Cancer Center)
Cited by 6
Related Papers
Antibody-drug conjugates in lung cancer: dawn of a new era?
|npj Precision Oncology|2023|116